DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 50-750/S-003
NDA 50-684/S-015

Wyeth-Ayerst Research
Attention: Roberta R. Acchione
Associate Director
U.S. Regulatory Affairs
170 North Radnor-Chester Road
Saint Davids, Pennsylvania 19087

Dear Ms. Acchione:

Please refer to your supplemental new drug applications dated July 6, 1999 (NDA 50-750) and July 7, 1999 (NDA 50-684), received July 8, 1999 and July 13, 1999, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zosyn® (sterile piperacillin sodium and tazobactam sodium injection) in Galaxy® Containers (NDA 50-750) and Zosyn® (sterile piperacillin sodium and tazobactam sodium) (NDA 50-684). We note that this application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

These "Changes Being Effected" supplemental new drug applications provide for updating the **ADVERSE REACTIONS** section of the labeling with addition of **hemolytic anemia** as a new adverse drug term and insertion of the terms **hepatitis** and **cholestatic jaundice** to replace "cholestatic hepatitis". In addition, **erythema multiforme** and **Stevens-Johnson syndrome** were moved forward in the **ADVERSE REACTIONS** section.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter. We strongly suggest that you submit a prior approval supplement to update the **Microbiology** subsection of the label.

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 50-684/S-015, 50-750/S-003." Approval of these submissions by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Susmita Samanta, M.D., Regulatory Project Manager, at (301) 827-2125.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Janice Soreth

3/27/02 03:25:14 PM